Analyst Price Targets — IQV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 29, 2026 1:53 pm | — | RBC Capital | $247.00 | $246.03 | TheFly | Iqvia price target raised to $247 from $221 at RBC Capital |
| July 29, 2026 12:09 pm | Sean Dodge | BMO Capital | $270.00 | $249.51 | TheFly | Iqvia price target raised to $270 from $210 at BMO Capital |
| July 29, 2026 10:43 am | Eric Coldwell | Robert W. Baird | $287.00 | $243.31 | TheFly | Iqvia price target raised to $287 from $252 at Baird |
| July 13, 2026 11:43 am | Ann Hynes | Mizuho Securities | $230.00 | $207.85 | TheFly | Iqvia price target raised to $230 from $215 at Mizuho |
| July 9, 2026 12:33 pm | — | Deutsche Bank | $240.00 | $208.00 | TheFly | Iqvia named short-term buy idea at Deutsche Bank |
| July 6, 2026 2:22 pm | Sidharth Sahoo | HSBC | $240.00 | $206.42 | TheFly | Iqvia price target raised to $240 from $210 at HSBC |
| July 1, 2026 10:31 am | — | Robert W. Baird | $249.00 | $193.22 | TheFly | Iqvia price target raised to $249 from $230 at Baird |
| June 17, 2026 10:31 am | Kallum Titchmarsh | Morgan Stanley | $200.00 | $179.17 | TheFly | Iqvia downgraded to Equal Weight from Overweight at Morgan Stanley |
| June 3, 2026 9:27 am | — | HSBC | $210.00 | $180.64 | TheFly | Iqvia price target lowered to $210 from $240 at HSBC |
| May 7, 2026 1:19 pm | — | Morgan Stanley | $225.00 | $179.31 | TheFly | Iqvia price target lowered to $225 from $240 at Morgan Stanley |
Latest News for IQV
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen…
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
Callan Family Office LLC bought a new position in IQVIA Holdings Inc. (NYSE: IQV) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,044 shares of the medical research company's stock, valued at approximately $1,747,000. Other hedge funds and other
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and IQVIA (NYSE: IQV - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Valuation and Earnings This table compares BioLife Solutions and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.